Addpharma

Korean pharma

Privately held: no public share price · South Korea

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporterSmall molecule
Hypertension
Phase 1
Undisclosed / early pipeline
Atherosclerotic Cardiovascular Disease
RosuvamibeNo recent activity
Preclinical / Unstaged
HMG-CoA reductase / NPC1L1Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 February 2026Topline resultAD-209AD-209 Phase III (NCT06348576) met non-inferiority and superiority versus telmisartan 40 mg
Addpharma · Source ↗

Financial reports

No financial reports recorded.